Recall events
/
Event 67228
Event summary
Timeline bucket January 09, 2014
Product types Drug
Classifications Class I
Statuses Terminated
Recalling firm wording Schindele Enterprises dba Midwest Wholesale
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
7 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 7
XZONE GOLD, 1 capsule blister 750 mg, Distributed by: XZONE, Orlando, FL.
D-1334-2014
Recall number D-1334-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 175 blister packs
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information Lot # 130710GL, Exp. 07/31/2018
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[9401]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 7
BOOST ULTRA, sexual enhancement dietary supplement, 12-capsule/bottle. Also packaged in 3 pill bottles and 1 pill packs. BoostUtra.com, Springfield, MO.
D-1335-2014
Recall number D-1335-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 500 1-ct blisters; 30 3-ct bottles, 4 12-ct bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information 12 pill bottle and 3 pill bottle: Lot # B70130 Exp. 03/15; 1 pill pack: Lot # 06012011 Exp 06/14.
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[6053]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 7
SEXY MONKEY, 2000 mg, 1 count blister, Distributed by A Herbal Bio, Inc., Bayside, NY.
D-1336-2014
Recall number D-1336-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 2 blister packs
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information NO LOT NUMBER, Exp 12/31/14
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[9400]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 7
MiracleZEN Platinum, 1 pill blister pack, 2000 mg capsule, Distributed by: Power Life Distributors, COK Inc., Los Angeles, CA.
D-1337-2014
Recall number D-1337-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 49 blister packs
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information 1 pill blister packs: Lot OAWF 1027 Exp 1/31/2015 and Lot OAWF1003 Exp 01/31/2015.
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[8446]
FDA event record
· Exact recall-number query on openFDA
drug · product 5 of 7
Magic For Men, packaged in 1ct blister pack and 12-pill/bottle, 390 mg Manufactured For: BTQ Ski, Inc., Chicago, IL 60638
D-1338-2014
Recall number D-1338-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 59/1-ct blister pack, 97/12-ct bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information 12-ct.bottle, Lot GP808, Exp. 10/16, 1-ct. blister Lot BN030613, EXP 020615
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[5944]
FDA event record
· Exact recall-number query on openFDA
drug · product 6 of 7
ExtenZe 600 mg, 30 tablet box, Manufactured for: Biotab Nutraceuticals, Inc., Pasadena, CA.
D-1339-2014
Recall number D-1339-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 57 boxes
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information Lot 0512058, Exp. 05/16
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[6022]
FDA event record
· Exact recall-number query on openFDA
drug · product 7 of 7
XZEN PLATINUM, 750 mg, Distributed by: XZEN, Los Angeles, CA.
D-1340-2014
Recall number D-1340-2014
Initiated January 09, 2014
Classification Class I
Status Terminated
Quantity 89 blister packs
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed Without an Approved NDA/ANDA: These dietary supplements contain undeclared sildenafil, an analogue of sildenafil, and/or tadalafil.
Code information Lot 130520PL Exp. 05/31/2017
Distribution pattern Distributed to PA, IL, TX, IA, GA, CT, FL, CA, LA, NY, MD, NV, and WI
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[8435]
FDA event record
· Exact recall-number query on openFDA
